Cell Therapeutics (CTI) has announced the European launch of Pixuvri for the treatment of adult patients with multiply relapsed or refractory aggressive non-hodgkin B-cell lymphoma.
The company initiated the launch with entry into Sweden, Denmark and Finland to be followed by Austria and Norway in early October 2012 and Germany, UK and the Netherlands in November 2012.
CTI considers expanding availability to France, Italy and Spain in addition to other European countries in 2013.
CTI president and CEO James Bianco said the company is able to offer the first meaningful treatment option for physicians treating those patients with multiply relapsed and refractory aggressive NHL.
"CTI looks forward to making this innovative product available to healthcare providers across the European Union," Bianco added.
Pixuvri is a novel aza-anthracenedione with distinctive structural and physio-chemical properties.
Expanding the reach of anthracyclines with piXanTronE in relapsed or refractory aggressive NHL Disease study for Pixuvri has demonstrated that more patients on Pixuvri achieved a complete response or unconfirmed complete response, and also survived for longer before the disease progressed.
